The challenges are mounting for Novo Nordisk A/S.
The drugmaker’s shares fell on Thursday after telehealth firm Hims & Hers Health Inc. launched a cheaper copycat version of Novo’s new weight-loss pill. It comes during a brutal week for the Danish drugmaker, which has lost $60 billion in market value after warning investors that sales could decline as much as 13% this year.
